Sisram Medical Ltd. announced that the registration application of Profhilo, an injectable product exclusively distributed by the Company in Mainland China, was accepted by the National Medical Products Administration (the " NMPA"). The Product is a buffered physiological solution of high molecular weight hyaluronic acid (H-HA) and low molecular weight hyaluronic Acid (L-HA). It uses NAHYCO®?

patented mixing technology to bring a better anti-aging experience to beauty seekers and patients. The Product has already been exclusively distributed in Israel, India and Hong Kong S.A.R through the Company's channels. In the event that the registration application is approved by the NMPA, it will enrich the Company's injectable product portfolio in Mainland China, promote the Company's product development and market penetration in the aesthetic field.

Shareholders and investors are advised to exercise caution when dealing in the securities of the Company.